Godavari Drugs Ltd
Godavari Drugs Ltd (GODAVARI) last traded at ₹100, a market capitalisation of ₹109 crore, on a P/E of 28.1. Over the past 52 weeks the stock has ranged between ₹69.7 and ₹135. Godavari Drugs Ltd last reported results for the quarter ended Jun 2026, with sales of ₹27.96 crore and net profit of ₹1.11 crore. Figures are as of 25 Aug 2026 and are not real time.
Godavari Drugs Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Godavari Drugs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹27.96 cr, up 17.4% from ₹23.81 cr a year earlier. Net profit was ₹1.11 cr, up 6.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 26.09 | 29.55 | 25.5 | 23.81 | 26.65 | 22.18 | 33.16 | 27.96 |
| Expenses | 23.19 | 26.97 | 22.39 | 20.91 | 24.65 | 19.71 | 30.22 | 25.44 |
| Operating profit | 2.9 | 2.58 | 3.11 | 2.9 | 2 | 2.47 | 2.94 | 2.52 |
| OPM % | 11.12% | 8.73% | 12.20% | 12.18% | 7.50% | 11.14% | 8.87% | 9.01% |
| Other income | 0.01 | 0.1 | 0.11 | 0.01 | 0.64 | 0.27 | 0.25 | 0.15 |
| Interest | 1.08 | 1.11 | 1.11 | 1 | 0.91 | 1.11 | 0.96 | 0.9 |
| Depreciation | 0.58 | 0.64 | 0.67 | 0.6 | 0.6 | 0.61 | 0.61 | 0.59 |
| Profit before tax | 1.25 | 0.93 | 1.44 | 1.31 | 1.13 | 1.02 | 1.62 | 1.18 |
| Tax % | 12.80% | 16.13% | 38.19% | 19.85% | 10.62% | 25.49% | 20.37% | 5.93% |
| Net profit | 1.09 | 0.77 | 0.89 | 1.04 | 1 | 0.76 | 1.29 | 1.11 |
| EPS (₹) | 1.45 | 1.02 | 1.18 | 1.38 | 1.33 | 1.01 | 1.27 | 1.10 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Godavari Drugs Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 123 | 161 | 160 | 157 | 113 | 106 | 110 |
| Operating profit | 10 | 11 | 10 | 13 | 12 | 10 | 10 |
| OPM % | 8% | 7% | 6% | 8% | 10% | 10% | 9% |
| Net profit | 4 | 5 | 4 | 6 | 4 | 4 | 4 |
| EPS (₹) | 5.48 | 6.97 | 5.03 | 7.37 | 5.82 | 4.04 | 4.71 |
TTM is the trailing twelve months to the most recent quarter.
Godavari Drugs Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- -3%
- 3 Years
- -13%
- TTM
- 5%
- 10 Years
- 11%
- 5 Years
- -2%
- 3 Years
- 2%
- TTM
- 3%
- 10 Years
- 9%
- 5 Years
- 6%
- 3 Years
- -3%
- 1 Year
- 17%
- 10 Years
- 11%
- 5 Years
- 12%
- 3 Years
- 10%
- Last Year
- 6%
Godavari Drugs Ltd shareholding pattern
Promoters held 40.23% at Jun 2026, down from 52.63% at Jun 2025. DIIs 2.74%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 52.63% | 52.63% | 52.63% | 52.63% | 52.61% | 52.61% | 40.23% | 40.23% |
| DIIs | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 2.47% | 2.74% |
| Public | 46.87% | 46.87% | 46.87% | 46.87% | 46.90% | 46.89% | 57.31% | 57.04% |
| No. of shareholders | 7,709 | 7,915 | 7,881 | 7,828 | 7,720 | 7,483 | 7,300 | 6,722 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Godavari Drugs Ltd corporate filings
- Submission of Statement on Deviation or Variation in uitilisation of Funds for the quarter ended 30 june 2026Company Updatelow impact
Cruxal's analysis: Godavari Drugs Ltd has filed its statement regarding the deviation or variation in the…
Read the full analysis - Newspaper Publication of Unaudited Results for quarter ended 30.06.2026Company Updatelow impact
Cruxal's analysis: Godavari Drugs Limited has submitted its unaudited financial results for the quarter…
Read the full analysis - Board of Directors of the Company in its meeting held on Friday, 14th August, 2026 at 11.45 A.M. approved and passed the resolution for allotment of Equity Shares on conversion of 7,86,690 ....Company Updatemedium impact
Cruxal's analysis: Godavari Drugs Ltd has approved the allotment of 7,86,690 equity shares to the promoter…
Read the full analysis - Submission of Un-Audited Standalone Financial Results for the Quarter ended as on June 30, 2026Resultmedium impact
Cruxal's analysis: Godavari Drugs Limited reported Q1 FY27 revenue from operations of 27.96 crore…
Read the full analysis - Submission of Un-Audited Standalone Financial Results for the Quarter ended as on June 30, 2026 and Allotment of Equity Shares on conversion of 7,86,690 (Seven Lakhs Eighty-Six Thousand ....Board Meetingmedium impact
Cruxal's analysis: Godavari Drugs Limited reported Q1 FY27 revenue from operations of 27.96 crore, down from…
Read the full analysis - Godavari Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Update on board meeting - Intimation ....Board Meetinglow impact
Cruxal's analysis: Godavari Drugs Limited has issued a formal corrigendum to rectify a typographical error…
Read the full analysis - Godavari Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Un-audited Financial Results ....Board Meetinglow impact
Cruxal's analysis: Godavari Drugs Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Godavari Drugs Ltd
Cruxal reads every Godavari Drugs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.